800P Number needed to treat (NNT) and number needed to harm (NNH) to estimate clinical efficacy and safety of new adjuvant (Adj) therapies for resected stage (St) II-III melanoma

D Zara,B Pastò,M Garutti,M Bartoletti,L Palmero,E Bertoli,C Noto,L Cucciniello,F Totaro,M Rizzetto,T Pivetta,A Membrino,A Freschi,S Bolzonello,F Puglisi

doi:10.1016/j.annonc.2022.07.926

800P Number needed to treat (NNT) and number needed to harm (NNH) to estimate clinical efficacy and safety of new adjuvant (Adj) therapies for resected stage (St) II-III melanoma

D Zara, B Pastò + Show 13 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.926

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
Citations: 1

Affiliation: University of Udine

#Number Needed To Harm #Number Needed To Treat + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

NNT and NNH are simple, easy-to-read devices that allow to estimate magnitude of benefit and harm of a therapeutic intervention. This study aims to apply these numbers to describe efficacy and safety of pembrolizumab (Pembro) and dabrafenib plus trametinib (D-T) as Adj therapies in St II-III resected melanoma.

Full Text